James L Li

Dr. James L Li

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 May 2024 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
GJGuochong Jia
Guochong Jia
JPJie Ping
Jie Ping
XGXingyi Guo
Xingyi Guo
YYYaohua Yang
Yaohua Yang
RTRan Tao
Ran Tao
WZWei Zheng
Wei Zheng

5 April 2021 in GigaScience
Verified
Journal Article
Open access
PDF file
JGJeffrey B S Gaither
Jeffrey B S Gaither
GLGrant E Lammi
Grant E Lammi
JLJames L Li
James L Li
DGDavid M Gordon
David M Gordon
HKHarkness C Kuck
Harkness C Kuck
PWPeter White
Peter White
Background: The role of synonymous single-nucleotide variants in human health and disease is poorly understood, yet evidence suggests that this class of “silent” genetic variation plays multiple regulatory roles in both transcription and translation. One mechanism by which synonymous codons direct and modulate the translational process is through alteration of the elaborate structure formed by single-stranded mRNA molecules. While tools to computationally predict the effect of non-synonymous variants on protein structure are plentiful, analogous tools to systematically assess how synonymous variants might disrupt mRNA structure are lacking. Results: We developed novel software using a parallel processing framework for large-scale generation of secondary RNA structures and folding statistics for the transcriptome of any species. Focusing our analysis on the human transcriptome, we calculated 5 billion RNA-folding statistics for 469 million single-nucleotide variants in 45,800 transcripts. By considering the impact of all possible synonymous variants globally, we discover that synonymous variants predicted to disrupt mRNA structure have significantly lower rates of incidence in the human population. Conclusions: These findings support the hypothesis that synonymous variants may play a role in genetic disorders due to their effects on mRNA structure. To evaluate the potential pathogenic impact of synonymous variants, we provide RNA stability, edge distance, and diversity metrics for every nucleotide in the human transcriptome and introduce a “Structural Predictivity Index” (SPI) to quantify structural constraint operating on any synonymous variant. Because no single RNA-folding metric can capture the diversity of mechanisms by which a variant could alter secondary mRNA structure, we generated a SUmmarized RNA Folding (SURF) metric to provide a single measurement to predict the impact of secondary structure altering variants in human genetic studies.

8 August 2024 in Epigenetics & Chromatin
Verified
Journal Article
Open access
PDF file
NJNiyati Jain
Niyati Jain
JLJames L Li
James L Li
LTLin Tong
Lin Tong
FJFarzana Jasmine
Farzana Jasmine
MKMuhammad G. Kibriya
Muhammad G. Kibriya
BPBrandon L. Pierce
Brandon L. Pierce
While the association of chronological age with DNA methylation (DNAm) in whole blood has been extensively studied, the tissue-specificity of age-related DNAm changes remains an active area of research. Studies investigating the association of age with DNAm in tissues such as brain, skin, immune cells, fat, and liver have identified tissue-specific and non-specific effects, thus, motivating additional studies of diverse human tissue and cell types. Here, we performed an epigenome-wide association study, leveraging DNAm data (Illumina EPIC array) from 961 tissue samples representing 9 tissue types (breast, lung, colon, ovary, prostate, skeletal muscle, testis, whole blood, and kidney) from the Genotype-Tissue Expression (GTEx) project. We identified age-associated CpG sites (false discovery rate < 0.05) in 8 tissues (all except skeletal muscle, n = 47). This included 162,002 unique hypermethylated and 90,626 hypomethylated CpG sites across all tissue types, with 130,137 (80%) hypermethylated CpGs and 74,703 (82%) hypomethylated CpG sites observed in a single tissue type. While the majority of age-associated CpG sites appeared tissue-specific, the patterns of enrichment among genomic features, such as chromatin states and CpG islands, were similar across most tissues, suggesting common mechanisms underlying cellular aging. Consistent with previous findings, we observed that hypermethylated CpG sites are enriched in regions with repressed polycomb signatures and CpG islands, while hypomethylated CpG sites preferentially occurred in non-CpG islands and enhancers. To gain insights into the functional effects of age-related DNAm changes, we assessed the correlation between DNAm and local gene expression changes to identify age-related expression quantitative trait methylation (age-eQTMs). We identified several age-eQTMs present in multiple tissue-types, including in the CDKN2A, HENMT1, and VCWE regions. Overall, our findings will aid future efforts to develop biomarkers of aging and understand mechanisms of aging in diverse human tissue types.

9 May 2023 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
GGGuimin Gao
Guimin Gao
PFPeter N. Fiorica
Peter N. Fiorica
JMJulian McClellan
Julian McClellan
ABAlvaro N. Barbeira
Alvaro N. Barbeira
JLJames L Li
James L Li
DHDezheng Huo
Dezheng Huo

14 March 2024 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
JLJames L Li
James L Li
NJNiyati Jain
Niyati Jain
LTLizeth I. Tamayo
Lizeth I. Tamayo
LTLin Tong
Lin Tong
FJFarzana Jasmine
Farzana Jasmine
BPBrandon L. Pierce
Brandon L. Pierce

1 May 2024 in JAMA Network Open
Verified
Journal Article
Open access
PDF file
JFJincong Q. Freeman
Jincong Q. Freeman
JLJames L Li
James L Li
SFSusan G. Fisher
Susan G. Fisher
KYKatharine A. Yao
Katharine A. Yao
SDSean P. David
Sean P. David
DHDezheng Huo
Dezheng Huo
In the US, breast cancer (BC) is the most common malignant neoplasm and the second leading cause of cancer deaths among women, with an estimated 287 850 new diagnoses and 43 250 deaths in 2022.1,2 BC diagnosis and treatment can take a heavy toll on patients’ physical, mental, psychosocial, and financial health. Cancer treatment and care services require interdisciplinary and multidisciplinary collaborations and effective patient-clinician communication and shared decision-making, while respecting patient autonomy.3 Some patients with cancer choose to decline treatment despite clinician recommendations and treatment benefits. Declining curative treatment can have a detrimental effect on these patients’ short-term and long-term health outcomes and quality of life.4-6 Studies have documented elevated risks of all-cause and disease-specific mortality in patients with cancer who forgo treatment recommended by their clinicians.7-11